Spots Global Cancer Trial Database for AZD6738 Plus Durvalumab in Biliary Tract Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: AZD6738 Plus Durvalumab in Biliary Tract Cancer
Official Title: Combination of AZD6738 Plus Durvalumab in Refractory Biliary Tract Cancer in Patients Who Have Failed Immunotherapy
Study ID: NCT04298008
Study Description
Brief Summary: This trial will enroll advanced biliary tract cancer patients who have been previously treated with immunotherapy in either the 2nd or 3rd line. Patients will be treated with AZD6738 and Durvalumab combination.
Detailed Description: This is a single arm, phase II study. Advanced BTC patients who have been previously treated with immunotherapy in either the 2nd or 3rd line will be enrolled. Patients will be treated with AZD6738 and Durvalumab combination. One cycle consists of 4weeks. Response evaluation will be done every 8 weeks (every 2 cycles) of treatment 1. Tumor biopsy is mandatory: screening, after 8weeks (1st-response evaluation), at disease progression (PD) 2. blood sampling for biomarker study is mandatory: every cycles 3. To evaluate the metabolic changes by AZD6738 and Durvalumab combination : 18 F-FDG PET is mandatory : screening, after 8 weeks (1st-response evaluation)
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Seoul National University Hospital, Seoul, , Korea, Republic of
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
